[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100539934":3},{"organization":4,"armGroups":7,"interventions":38,"overallOfficials":44,"centralContacts":44,"locations":50,"responsibleParty":290,"collaborators":44,"id":292,"slug":44,"hasResults":293,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":44,"eligibilityCriteria":297,"healthyVolunteers":293,"sex":298,"minAge":299,"maxAge":300,"enrollmentInfo":301,"targetDuration":44,"studyType":304,"phases":305,"briefSummary":307,"conditions":308,"keywords":44,"overallStatus":53,"whyStopped":44,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":319},{"fullName":5,"class":6},"Barinthus Biotherapeutics","INDUSTRY",[8,14,20,23,26,29,32,35],{"label":9,"type":10,"description":11,"interventionNames":12},"Matched Placebo (SAD)","PLACEBO_COMPARATOR","2 placebo comparators; 1 for each part of the study",[13],"Other: Matched Placebo",{"label":15,"type":16,"description":17,"interventionNames":18},"VTP-1000 Dose 1 (SAD)","EXPERIMENTAL","3 dose levels in SAD and MAD parts of trial",[19],"Biological: VTP-1000",{"label":21,"type":16,"description":17,"interventionNames":22},"VTP-1000 Dose 2 (SAD)",[19],{"label":24,"type":16,"description":17,"interventionNames":25},"VTP-1000 Dose 3 (SAD)",[19],{"label":27,"type":10,"description":11,"interventionNames":28},"Matched Placebo (MAD)",[13],{"label":30,"type":16,"description":17,"interventionNames":31},"VTP-1000 Dose 1 (MAD)",[19],{"label":33,"type":16,"description":17,"interventionNames":34},"VTP-1000 Dose 2 (MAD)",[19],{"label":36,"type":16,"description":17,"interventionNames":37},"VTP-1000 Dose 3 (MAD)",[19],[39,45],{"type":40,"name":41,"description":42,"armGroupLabels":43,"otherNames":44},"BIOLOGICAL","VTP-1000","Intramuscular (IM) injection comprised of self-assembling nanoparticles of gluten peptides and a rapamycin component",[30,15,33,21,36,24],null,{"type":46,"name":47,"description":48,"armGroupLabels":49,"otherNames":44},"OTHER","Matched Placebo","Intramuscular (IM) injection comprised of saline solution",[27,9],[51,70,85,100,114,127,142,156,171,185,200,215,230,245,260,275],{"facility":52,"status":53,"city":54,"state":55,"zip":56,"country":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"Parexel EPCU LA","RECRUITING","Los Angeles","California","91206","United States",{"type":59,"coordinates":60},"Point",[61,62],-118.24368,34.05223,{"lat":62,"lon":61},[65],{"name":66,"role":67,"phone":68,"phoneExt":44,"email":69},"Jess Mehrasaz","CONTACT","626-298-2756","jess.mehrsaz@parexel.com",{"facility":71,"status":53,"city":72,"state":73,"zip":74,"country":57,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Peak Gastroenterology Associates","Colorado Springs","Colorado","80907",{"type":59,"coordinates":76},[77,78],-104.82136,38.83388,{"lat":78,"lon":77},[81],{"name":82,"role":67,"phone":83,"phoneExt":44,"email":84},"Rutva Nakarani","719-636-1201","rnakarani@peakgastro.com",{"facility":86,"status":53,"city":87,"state":88,"zip":89,"country":57,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Jacksonville Center for Clinical Research","Jacksonville","Florida","32216",{"type":59,"coordinates":91},[92,93],-81.65565,30.33218,{"lat":93,"lon":92},[96],{"name":97,"role":67,"phone":98,"phoneExt":44,"email":99},"Sara Villotti","904-730-0101","svillotti@encoredocs.com",{"facility":101,"status":53,"city":102,"state":88,"zip":103,"country":57,"cosmosGeoPoint":104,"geoPoint":108,"contacts":109},"GCP Research","St. Petersburg","33705",{"type":59,"coordinates":105},[106,107],-82.67927,27.77086,{"lat":107,"lon":106},[110],{"name":111,"role":67,"phone":112,"phoneExt":44,"email":113},"Jessica Cruz","727-520-1427","jcruz@researchgcp.com",{"facility":115,"status":53,"city":116,"state":117,"zip":118,"country":57,"cosmosGeoPoint":119,"geoPoint":123,"contacts":124},"Parexel EPCU Baltimore","Baltimore","Maryland","21225",{"type":59,"coordinates":120},[121,122],-76.61219,39.29038,{"lat":122,"lon":121},[125],{"name":126,"role":67,"phone":68,"phoneExt":44,"email":69},"Jess Mehrsaz",{"facility":128,"status":53,"city":129,"state":130,"zip":131,"country":57,"cosmosGeoPoint":132,"geoPoint":136,"contacts":137},"Clinical Research Institute of Michigan","Clinton Township","Michigan","48038",{"type":59,"coordinates":133},[134,135],-82.91992,42.58698,{"lat":135,"lon":134},[138],{"name":139,"role":67,"phone":140,"phoneExt":44,"email":141},"Molly Wythe","586-598-3329","mwythe@researchmi.com",{"facility":143,"status":53,"city":144,"state":130,"zip":145,"country":57,"cosmosGeoPoint":146,"geoPoint":150,"contacts":151},"West Michigan Clinical Research Center","Wyoming","49159",{"type":59,"coordinates":147},[148,149],-85.70531,42.91336,{"lat":149,"lon":148},[152],{"name":153,"role":67,"phone":154,"phoneExt":44,"email":155},"Rochelle Copeland","616-328-5344","rcopeland@gastro-assoc-wm.com",{"facility":157,"status":53,"city":158,"state":159,"zip":160,"country":57,"cosmosGeoPoint":161,"geoPoint":165,"contacts":166},"Mayo Clinic","Rochester","Minnesota","55905",{"type":59,"coordinates":162},[163,164],-92.4699,44.02163,{"lat":164,"lon":163},[167],{"name":168,"role":67,"phone":169,"phoneExt":44,"email":170},"Chadrick Hinson","507-266-0237","Hinson.chadrick@mayo.edu",{"facility":172,"status":53,"city":173,"state":173,"zip":174,"country":57,"cosmosGeoPoint":175,"geoPoint":179,"contacts":180},"NYU Langone - Gastroenterology Associates","New York","10016",{"type":59,"coordinates":176},[177,178],-74.00597,40.71427,{"lat":178,"lon":177},[181],{"name":182,"role":67,"phone":183,"phoneExt":44,"email":184},"Valeria Pasuizaca-Yanez","212-263-3095","Valeria.Pasuizaca-Yanez@nyulangone.org",{"facility":186,"status":53,"city":187,"state":188,"zip":189,"country":57,"cosmosGeoPoint":190,"geoPoint":194,"contacts":195},"North Carolina Clinical Research","Raleigh","North Carolina","27607",{"type":59,"coordinates":191},[192,193],-78.63861,35.7721,{"lat":193,"lon":192},[196],{"name":197,"role":67,"phone":198,"phoneExt":44,"email":199},"Daunita Audesuyi","919-881-0309","dadesuyi@nccr.com",{"facility":201,"status":53,"city":202,"state":203,"zip":204,"country":57,"cosmosGeoPoint":205,"geoPoint":209,"contacts":210},"Centricity Research","Columbus","Ohio","43213",{"type":59,"coordinates":206},[207,208],-82.99879,39.96118,{"lat":208,"lon":207},[211],{"name":212,"role":67,"phone":213,"phoneExt":44,"email":214},"Stephanie Scarberry","614-501-6164","Stephanie.Scarberry@centricityresearch.com",{"facility":216,"status":53,"city":217,"state":218,"zip":219,"country":57,"cosmosGeoPoint":220,"geoPoint":224,"contacts":225},"Vanderbilt University Medical Center","Nashville","Tennessee","37232",{"type":59,"coordinates":221},[222,223],-86.78444,36.16589,{"lat":223,"lon":222},[226],{"name":227,"role":67,"phone":228,"phoneExt":44,"email":229},"Mary Vozar","615-936-1288","mary.c.vozar@vumc.org",{"facility":231,"status":53,"city":232,"state":233,"zip":234,"country":57,"cosmosGeoPoint":235,"geoPoint":239,"contacts":240},"PPD Research Unit","Austin","Texas","78744",{"type":59,"coordinates":236},[237,238],-97.74306,30.26715,{"lat":238,"lon":237},[241],{"name":242,"role":67,"phone":243,"phoneExt":44,"email":244},"Al Gonzalez","512-747-4656","Al.Gonzalez@ppd.com",{"facility":246,"status":53,"city":247,"state":248,"zip":249,"country":57,"cosmosGeoPoint":250,"geoPoint":254,"contacts":255},"Velocity Clinical Research, Salt Lake City","West Jordan","Utah","84088",{"type":59,"coordinates":251},[252,253],-111.9391,40.60967,{"lat":253,"lon":252},[256],{"name":257,"role":67,"phone":258,"phoneExt":44,"email":259},"Srinivas Mulamalla","801-542-8190","smulamalla@velocityclinical.com",{"facility":261,"status":53,"city":262,"state":263,"zip":264,"country":57,"cosmosGeoPoint":265,"geoPoint":269,"contacts":270},"Clinical Research Partners","Richmond","Virginia","23226",{"type":59,"coordinates":266},[267,268],-77.46026,37.55376,{"lat":268,"lon":267},[271],{"name":272,"role":67,"phone":273,"phoneExt":44,"email":274},"Aundraya Bray","804-477-3045","at@clinicalresearchrva.com",{"facility":276,"status":53,"city":277,"state":278,"zip":279,"country":57,"cosmosGeoPoint":280,"geoPoint":284,"contacts":285},"Velocity Clinical Research, Seattle","Seattle","Washington","98105",{"type":59,"coordinates":281},[282,283],-122.33207,47.60621,{"lat":283,"lon":282},[286],{"name":287,"role":67,"phone":288,"phoneExt":44,"email":289},"Luis Casanova","206-710-1574","lcasanova@velocityclinical.com",{"type":291,"investigatorFullName":44,"investigatorTitle":44,"investigatorAffiliation":44,"oldNameTitle":44,"oldOrganization":44},"SPONSOR","100539934",false,"NCT06310291","VTP-1000 in Adults With Celiac Disease","A Phase 1, First in Human, Randomized, Placebo-controlled Trial With a Controlled Gluten Challenge to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of VTP-1000 in Adults With Celiac Disease","Inclusion Criteria:\n\n* Diagnosis of celiac disease as confirmed by positive serology and intestinal histology\n* Presence of Human Leukocyte Antigen (HLA)-DQ2.5 genotype\n* Participants who are on a well controlled gluten restricted diet\n* Anti-tissue transglutaminase (tTG) IgA antibodies less than 2 times the upper limit of normal and anti-deamidated gliadin peptide IgG (anti-DGP)-IgA\u002FIgA antibodies less than 3 times the upper limit of normal\n* Non-pregnant or breast feeding females\n* No other clinical significant findings at screening\n\nExclusion Criteria:\n\n* Refractory celiac disease\n* Selective IgA deficiency\n* Positive for HLA-DQ8\n* Known wheat allergy or that is Type I hypersensitivity\n* Active inflammatory bowel disease or other condition with symptoms that will be similar to celiac disease","ALL","18 Years","70 Years",{"count":302,"type":303},45,"ESTIMATED","INTERVENTIONAL",[306],"EARLY_PHASE1","GLU001 is a first-in-human clinical trial to assess the safety and tolerability of VTP-1000 for adults with celiac disease. This trial will assess VTP-1000 at various dose levels compared to placebo in a single ascending dose (SAD) and multiple ascending dose (MAD) format. Participants will be followed for a short period of time to assess the impact of VTP-1000 on their immune system (Adverse events, reactions in the blood, and physical exam differences). Participants enrolled in the MAD portion of the trial will undergo a gluten challenge to assess the impact exposure to gluten has on participants after administration of VTP-1000.",[309],"Celiac Disease","2026-06-17",{"date":312,"type":313},"2026-06-18","ACTUAL",{"date":315,"type":313},"2024-08-01",{"date":317,"type":303},"2026-11",{"name":5,"class":6},16]